AdaptHealth Corp. (NASDAQ:AHCO) Receives $10.70 Consensus Target Price from Analysts

Shares of AdaptHealth Corp. (NASDAQ:AHCO - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.36.

AHCO has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an "outperform" rating and issued a $13.00 price target on shares of AdaptHealth in a report on Monday, August 12th. Canaccord Genuity Group decreased their target price on AdaptHealth from $14.00 to $13.00 and set a "buy" rating on the stock in a research report on Wednesday. UBS Group cut their price target on AdaptHealth from $13.00 to $12.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Robert W. Baird lowered their target price on AdaptHealth from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Wednesday.

AdaptHealth Price Performance

NASDAQ:AHCO traded up $0.89 during trading hours on Wednesday, hitting $10.07. 1,495,926 shares of the stock traded hands, compared to its average volume of 1,063,358. The stock has a 50 day moving average price of $10.76 and a 200 day moving average price of $10.44. The company has a quick ratio of 0.94, a current ratio of 1.15 and a debt-to-equity ratio of 1.38. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -1.88, a price-to-earnings-growth ratio of 1.63 and a beta of 1.11. AdaptHealth has a 1 year low of $6.37 and a 1 year high of $11.90.

AdaptHealth (NASDAQ:AHCO - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.02). AdaptHealth had a positive return on equity of 9.58% and a negative net margin of 21.20%. The firm had revenue of $805.90 million during the quarter, compared to the consensus estimate of $809.32 million. During the same period in the prior year, the company posted $0.19 EPS. The company's quarterly revenue was up .2% on a year-over-year basis. Sell-side analysts forecast that AdaptHealth will post 0.87 EPS for the current fiscal year.

Insider Transactions at AdaptHealth

In other AdaptHealth news, COO Shaw Rietkerk sold 25,000 shares of the company's stock in a transaction on Friday, September 20th. The shares were sold at an average price of $11.24, for a total value of $281,000.00. Following the sale, the chief operating officer now directly owns 212,611 shares of the company's stock, valued at approximately $2,389,747.64. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director David Solomon Williams III sold 4,000 shares of the firm's stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $11.26, for a total transaction of $45,040.00. Following the sale, the director now directly owns 36,899 shares in the company, valued at $415,482.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Shaw Rietkerk sold 25,000 shares of the company's stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $11.24, for a total value of $281,000.00. Following the transaction, the chief operating officer now directly owns 212,611 shares of the company's stock, valued at approximately $2,389,747.64. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.43% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Covestor Ltd lifted its position in shares of AdaptHealth by 279.6% during the 1st quarter. Covestor Ltd now owns 3,109 shares of the company's stock worth $36,000 after purchasing an additional 2,290 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of AdaptHealth in the 2nd quarter valued at about $58,000. Blue Trust Inc. acquired a new stake in shares of AdaptHealth during the 2nd quarter worth about $85,000. Innealta Capital LLC purchased a new stake in AdaptHealth during the second quarter worth approximately $101,000. Finally, Quest Partners LLC boosted its holdings in AdaptHealth by 11,522.7% in the second quarter. Quest Partners LLC now owns 10,228 shares of the company's stock valued at $102,000 after purchasing an additional 10,140 shares in the last quarter. Hedge funds and other institutional investors own 82.67% of the company's stock.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.